BSG and rheumatoid arthritis: Tocilizumab treatment decreased circulating EMMPRIN/CD147 levels in serum samples from RA patients, enhanced the expression of circulating miR-146a-5p and miR-150-5p, and reduced angiogenic potential, which was manifested by a reduced number of tubular structures formed by the EaHy926 endothelial cell line (Zisman et al., 2021).